Utility of laboratory screening for inherited thrombophilia
in the acute setting for hospitalized pediatric patients
Ella Dolan MD, MPH, Jason Koury, PharmD, Angela Feng, MS-II, Shirley Abraham, MD
Department of Pediatrics
The University of New Mexico
Presenter: Ella Dolan, edolan@salud.unm.edu
INTRODUCTION

METHODS

DISCUSSION AND SUMMARY

Pediatric patients with thromboembolic events (TEEs) often undergo
testing for inherited thrombophilia disorders1, including anti-thrombin III
deficiency, Factor V Leiden mutation, prothrombin 20210 mutation
(Factor II mutation), protein C deficiency, and protein S deficiency. While
Manco-Johnson et al. recommended testing for the above defects,
amongst others, in all pediatric patients with thrombosis2, there is
increasing evidence that this often does not result in meaningful changes
in management1,3,4 and may not be cost effective1. Nakashami et al.
recommends a stepwise testing algorithm to optimize diagnosis while
preventing excessive testing, also noting the importance of avoiding
testing other than DNA analysis in the acute setting of a thrombotic
event.5

Data is collected via retrospective chart review of pediatric patients ≥ 1 year to < 18 years
who underwent laboratory analysis to screen for inherited thrombophilia disorders during
inpatient hospitalization from 02/01/2011 to 01/31/2021. All records and information will be
accessed and reviewed through the UNM Hospital Cerner electronic medical record.
Charts will be identified and reviewed for listed study personnel on the IRB application.
Exclusion Criteria include infants <1 year or adults (≥ 18 years) using age at the time of
testing, children with a previously diagnosed inherited thrombophilia disorder, pregnant
women and prisoners, children with laboratory analysis done for reasons other than
thrombosis (e.g., children without diagnosis of thrombotic event), and incomplete data on
chart review. Data will be entered into REDCap. The primary and secondary outcomes will
be analyzed using descriptive statistics.

Our results are in the process of being obtained. In summary, this
study aims to clarify the utility of inpatient testing for inherited
thrombophilia disorders in pediatric patients with an emphasis on
the clinical impact of this testing. Considerations regarding if and
when to test for inherited thrombophilia disorders should include the
frequency and degree of clinical management changes as a result
of testing, as well as patient characteristics that may make it more
or less likely to identify a meaningful inherited thrombophilia
disorder. Additionally, cost effectiveness should be considered and
may be influenced by the setting in which testing is undertaken. We
hope to contribute to the existing body of research regarding this
topic to optimize recommendations for when inherited thrombophilia
testing should be pursued in pediatric patients.

According to the CDC, a 2016 Journal of Hospital Medicine article cited a
cost to Medicare of $300 million to $670 million in “unnecessary”
thrombophilia testing.6 Furthermore, Gavva et al. estimated an annual
cost of $82,000 for thrombophilia testing in pediatric patients and notes
the potential harm of additional blood draws.1 While thrombotic events in
pediatric patients have increased in recent years, the proportion of these
with an underlying etiology of inherited thrombophilia is quite variable.7
A 2008 meta-analysis demonstrated an association between recurrent
VTE and “protein C, protein S, and antithrombin deficiency; factor II
variant; and ≥2 genetic traits” in children, but did not find the same
association with “factor V mutation or elevated lipoprotein(s)”.8 Raffini and
Thornburg7 cite sources explaining that the impact of inherited
thrombophilia testing on clinical outcomes and practice guidelines has
not been well demonstrated; furthermore, a 2012 supplement in CHEST
suggests that there is not enough evidence to either support nor oppose
the use of thrombophilia markers to guide duration or intensity of therapy
as a separate factor from clinical data, such as the unprovoked versus
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recommendation from this publication is to follow the same
anticoagulation therapy protocol regardless of “inherited thrombophilia
risk factors”.9 Additional investigation to further characterize the utility of
inherited thrombophilia testing in pediatric patients is warranted, at least
in part to determine to what extent testing may tangibly impact
management decisions.

STUDY OBJECTIVES
The purpose of this study is to determine the utility of inpatient testing for
inherited thrombophilia disorders in pediatric patients.
Primary Outcome:
To determine the percentage of pediatric patients for whom laboratory
analysis screening confirmed a diagnosis of an inherited thrombophilia
disorder.
Secondary Outcomes:
A. To determine what proportion of pediatric patients with confirmed
diagnosis of an inherited thrombophilia disorder had a change in
management (e.g., initiation of anti-coagulation, change in duration of
anti-coagulation therapy) based on this diagnosis.
B. To determine the average length of time from diagnosis to clinical
management change for those patients in whom a confirmed inherited
thrombophilia diagnosis altered therapy.

Patient demographic data collected includes age, gender, race/ethnicity, weight, height,
BMI, and thrombosis risk factors (e.g., ICU, hormonal therapy, acute infection, autoimmune
disorder). Thrombophilia data collected includes thrombophilia-related diagnosis (e.g.,
VTE, PE, DVT, ischemic stroke), site of thromboembolic event (TEE), thrombophilia testing
performed (e.g., ATIII, protein C, protein S, Factor V Leiden, Prothrombin 20210 mutation
(Factor II mutation), anti-phospholipid, amongst others), results of thrombophilia-related
testing, location of thrombophilia-related testing (e.g., inpatient, outpatient), prior history of
TEE, and documented family history of thrombophilia-related diagnose(s) and/or inherited
thrombophilia disorder(s), if available. Clinical outcome data collected includes diagnosis of
inherited thrombophilia disorder, initiation of anti-coagulation therapy (yes/no), type of anticoagulation therapy (e.g., enoxaparin, heparin), duration of anti-coagulation therapy, and
duration or dose change of anti-coagulation therapy (based on diagnosis of inherited
thrombophilia disorder if able to assess).
Inclusion Criteria
Age ≥ 1 year to < 18 years
Thrombophilia-related diagnosis/thromboembolic
event (TEE)
Laboratory testing for at least one inherited
thrombophilia disorder performed

Exclusion Criteria
Infants (<1 year) or adults (≥ 18 years)
No thrombotic event (e.g., testing pursued as
screening due to autoimmune disorder)
Children with a previously diagnosed inherited
thrombophilia disorder
Initial laboratory testing associated with the TEE of
Initial laboratory testing associated with the TEE of
interest occurred before 2/1/2011 or after
interest occurred between 2/1/2011 and 1/31/2021
1/31/2021
Pregnant women and prisoners
Incomplete data on chart review

RESULTS
Planned results will include but are not limited to:
- Average age
- Percentage representation of gender
- Percent of TEE with apparent provocation
- Comparison of provocation rate in those later found to have inherited thrombophilia
disorder versus those without
- Average anti-coagulation duration
- Evaluation for whether there is a difference in duration for patients with identified
inherited thrombophilia disorder
- Percent with inherited thrombophilia disorder identified with laboratory analysis
- Location of laboratory analysis that identified inherited thrombophilia disorder, if
applicable
- Percent with change in anti-coagulation and characteristics of the change, including
what type of change was made and when the change was made
- Comparison of change in groups with versus without identified inherited
thrombophilia disorder
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